¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"central nervous system agents"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • central venous pressure monitoring
    Áß½ÉÁ¤¸Æ¾Ð°¨½Ã
  • central vision
    Á߽ɽÃ(·Â)
  • central visual acuity
    Á߽ɽ÷Â
  • central zone
    Á߽ɱ¸¿ª
  • Apgar scoring system
    ¾ÆÇÁ°¡Á¡¼öÆò°¡¹ý
  • array system
    ¹è¿­ÀåÄ¡, ¹è¿­Ã¼°è
  • auditory system
    û°¢°èÅë, û°¢°è
  • ABO blood group system
    ABOÇ÷¾×Çüü°è
  • air medical transport system
    Ç×°øÀÇ·á¼ö¼Ûü°è
  • alimentary system
    ¼ÒÈ­°èÅë, ¼ÒÈ­°è
  • Bethesda system
    º£µ¥½º´ÙºÐ·ù(¹ý)
  • biliary system
    ¾µ°³°èÅë, ´ãµµ°è
  • blood group system
    Ç÷¾×Çüü°è
  • buffer system
    ¿ÏÃæ°è
  • circuit system
    ¼øÈ¯½Äȸ·Î
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • central plasticity hypothesis
    ÁßÃßÀ¯¿¬¼º°¡¼³
  • central serous retinopathy
    Áß½ÉÀå¾×¸Á¸·º´Áõ
  • central trigeminal neuralgia
    ÁßÃß»ïÂ÷½Å°æÅë
  • central venous pressure
    Áß½ÉÁ¤¸Æ¾Ð
  • central venous pressure monitoring
    Áß½ÉÁ¤¸Æ¾Ð°¨½Ã
  • ABO blood group system
    ¿¡À̺ñ¿ÀÇ÷¾×Çü±º
  • aerospace life support system
    ¿ìÁÖ»ý¸íÀ¯Áö°èÅë
  • affectional system
    Á¤µ¿Ã¼°è, °¨Á¤Ã¼°è
  • alimentary system
    ¼ÒÈ­°èÅë
  • anaerobic culture system
    ¹«»ê¼Ò¹è¾ç±â
  • ancillary immune system
    º¸Á¶¸é¿ª°è
  • Apgar scoring system
    ¾ÆÇÁ°¡Á¡¼öÆò°¡¹ý
  • archicortical system
    ¿ø½Ã°ÑÁú°è
  • array system
    ¹è¿­ÀåÄ¡, ¹è¿­Ã¼°è
  • auditory system
    û°¢°èÅë
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • T system
    T°èÅë.
  • V-Tech urinalysis system
    V-Tech ¿äºÐ¼®Ã¼°è
  • Wiener system
    À§³Êü°è
  • Wilkerson point system
    ÀªÄ¿½¼Á¡¼öü°è
  • achromatic system
    ¹«»ö°è.
  • acid-base buffer system
    »ê¿°±â¿ÏÃæ°è
  • adrenal medulla,tumor of chemoreceptor system
    È­Çмö¿ëü°è Á¾¾ç(ûùùÊáôé»ô÷ͧ ðþåË)
  • adrenal system
    ºÎ½Å°è(Üùãìͧ).
  • aerospace life support system
    (Ç×°ø)¿ìÁÖ¿ë »ý¸íÀ¯Áö½Ã½ºÅÛ.
  • affectional system
    Á¤µ¿Ã¼°è
  • alimentary system(tract)
    ¼ÒÈ­±â°è(á¼ûùÐïͧ)
  • anemia expert system
    ºóÇ÷Àü¹®°¡½Ã½ºÅÛ
  • annular phased array system, APAS
    À§»óµ¿±âÀ±»ó¹è¿­½Ã½ºÅÛ
  • archicortical system
    ¿ø½ÃÇÇÁú°è(¡­Í§)
  • array system
    ¹è¿­ ÀåÄ¡ (¹è¿­ ü°è)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • oculomotor nervous branch
    ´«µ¹¸²½Å°æ°¡Áö
  • reactive nervous state
    ¹ÝÀÀ¼º ½Å°æ°ú¹Î»óÅÂ(ÚãëëàõãêÌèΦÚÂßÒ÷¾).
  • somatic nervous systema
    ü(¼º)½Å°æ°è(ô÷àõãêÌèÍ£).
  • subepidermal nervous plexus
    Ç¥ÇÇÇÏ ½Å°æ ¾ó±â
  • submucous nervous plexus
    Á¡¸·¹Ø½Å°æ¾ó±â
  • ala of central lobule
    Á߽ɼҿ±³¯°³
  • anterolateral central arteries anterolateral thalamostriate
    ¾Õ°¡ÂÊÁ߽ɵ¿¸Æ ¾Õ°¡ÂʽûóÁÙ¹«
  • anteromedial central arteries
    ¾Õ¾ÈÂÊÁ߽ɵ¿¸Æ
  • anteromedial central branches
    ¾Õ¾ÈÂÊÁ߽ɰ¡Áö
  • artery of central sulcus
    Á߽ɰí¶ûµ¿¸Æ
  • central
    Áß½É, ÁßÃß
  • central absence
    Á߽ɰῩÁõ
  • central action
    ÁßÃßÀÛ¿ë(ñéõÒíÂéÄ).
  • central amaurosis
    ÁßÃß¼ºÈæ¾Ï½Ã(ñéõÒàõýÙÒ®î¡).
  • central amputation
    Á᫐ Àý´Ü(ñéãýï·Ó¨), ÁßÃß(¼º) Àý´Ü, Áß¾Ó Àý´Ü(ñéäçï·Ó¨).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
MDS Master of Dental Surgery; maternal deprivation syndrome; medical data screening; medical data system...
MPS meconium plug syndrome; medial premotor system; Member of the Pharmaceutical Society; microbial prof...
NTV Nervous Tissue Vaccine; ½Å°æ Á¶Á÷ ¹é½Å
ARNMD Association for Research in Nervous and Mental Diseases
CNE chief nurse executive; chronic nervous exhaustion; concentric needle electrode
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
nr nervous
C- Central
C.A.R. Central African Republic
CAPD Central Auditory Processing Disorder
CCT Central Conduction Time
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • central nociceptive neuron
    ÁßÃß¼º Ä§ÇØ ¼ö¿ë¼º ´º¿ì·±, ÁßÃß À¯ÇØ ¼ö¿ë¼º ´º¿ì·±
  • central odontogenic fibroma
    °ñ³» Ä¡¼º ¼¶À¯Á¾
    Ä¡À¯µÎ°¡ °úÀ× Áõ½ÄµÈ °Í. ¾î¸°ÀÌ¿Í ÇϾǿ¡ Àß ¹ß°ßµÈ´Ù. ¿ÏÀüÇÑ ¿Ü°úÀû ÀûÃâÀÌ ¿ä±¸µÇ¸ç Àç¹ßÀº Àß ÇÏÁö ¾Ê´Â´Ù.
  • central pain
    ÁßÃßÅë, ÁßÃß¼º ÅëÁõ, ÁßÃß¼º µ¿Åë
    ÁßÃ߽Űæ°èÀÇ ÁÖµÈ º´¼Ò³ª ±â´ÉÀå¾Ö·Î ÀÎÇÑ ÅëÁõ.
  • central pain phenomenon
    ÁßÃß¼º µ¿Åë Çö»ó
  • central pain transmission cell
    ÁßÃß¼º ÅëÁõ Àü´Þ ¼¼Æ÷, ÁßÃß µ¿Åë Àü´Þ ¼¼Æ÷
  • central pain transmission pathway
    ÁßÃß¼º ÅëÁõ Àü´Þ °æ·Î, ÁßÃß µ¿ÅëÀü´Þ °æ·Î
  • central pathway
    ÁßÃß¼º °æ·Î, ÁßÃß °æ·Î
  • central point artifact
    Áß½ÉÁ¡ Àΰø¹°
  • central position
    Á߸³Àû À§Ä¡
  • central pulse
    Á᫐ ¸Æ¹Ú
  • central red pit
    Á߽ɼº Àû»ö ¼Ò¿Í
  • central renal echo complex
    ½Å Á᫐ ¿¡ÄÚ º¹ÇÕü
  • central retinal artery
    ¸Á¸· Á᫐ µ¿¸Æ
  • central retinal vein
    ¸Á¸· Á᫐ Á¤¸Æ
  • central ridge
    Áß¾Ó ´É¼±
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
antidepressive agents Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several monoamine oxidase inhibitors are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (antidepressive agents, tricyclic) also appear to act through brain catecholamine systems. A third group (antidepressive agents, second-generation) is a diverse group of drugs including some that act specifically on serotonergic systems.
(12 Dec 1998)
antidepressive agents, second-generation A structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake.
(12 Dec 1998)
antidepressive agents, tricyclic Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system.
(12 Dec 1998)
anti-dyskinesia agents Drugs used in the treatment of movement disorders. most of these act centrally on dopaminergic or cholinergic systems. Among the most important clinically are those used for the treatment of parkinson disease (antiparkinson agents) and those for the tardive dyskinesias.
(12 Dec 1998)
antifoaming agents Agents used to prevent the formation of foam or to treat flatulence or bloat.
(12 Dec 1998)
antifungal agents Agents destructive to fungi, suppressing their growth or reproduction, and effective against fungal infections. They differ from fungicides, industrial in that antifungal agents are restricted to action against fungi present in human or animal tissues.
(12 Dec 1998)
anti-HIV agents Agents used to treat aids and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with aids.
(12 Dec 1998)
antihypertensive agents Drugs used in the treatment of acute or chronic hypertension regardless of pharmacological mechanism. Among the antihypertensive agents are diuretics (especially diuretics, thiazide), adrenergic beta-antagonists, adrenergic alpha-antagonists, angiotensin-converting enzyme inhibitors, calcium channel blockers, ganglionic blockers, and vasodilator agents.
(12 Dec 1998)
anti-infective agents, local Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from disinfectants, which are used on inanimate objects.
(12 Dec 1998)
anti-infective agents, quinolone A group of synthetic antimicrobial agents which usually contain a 4-quinolinone ring structure. A few compounds belonging to this group have related nitrogen heterocyclic ring structures such as naphthyridine or phthalazine groups. All compounds in this group are substituted with an oxo group at the 4-position. The second-generation quinolones are also substituted with a 1-piperazinyl group at the 7-position and a fluorine moiety at the 6-position. The quinolones inhibit the a subunit of DNA gyrase and thus interfere with the ability of the enzyme to repair bacterial DNA breaks during replication. The compounds have a broad spectrum of activity against a variety of aerobic bacteria.
(12 Dec 1998)
anti-infective agents, urinary Substances capable of killing agents causing urinary tract infections or of preventing them from spreading.
(12 Dec 1998)
antilipaemic agents Substances that counteract high levels of lipids in the blood.
(12 Dec 1998)
antimanic agents Agents that are used to treat bipolar disorders or mania associated with other affective disorders.
(12 Dec 1998)
antimutagenic agents Agents that reduce the frequency or rate of spontaneous or induced mutations independently of the mechanism involved.
(12 Dec 1998)
antineoplastic and immunosuppressive agents Collective grouping for substances used to arrest the proliferation of malignant cells and those that suppress the immune response.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • decision support system
    (Àü»ê)(°æ¿µÀÇ)ÀÇ»ç °áÁ¤ Áö¿ø ½Ã½ºÅÛ
  • delayed time system
    (ÀüÀÚ)½Ã°£ Áö¿¬(ÃàÀû)¹æ½Ä
  • digestive system
    (ÇØ)¼ÒÈ­±â °èÅë(ÀÔ,À§,Àå µî)
  • domestic system
    °¡³» °ø¾÷ Á¦µµ
  • duples system
    (Àü»ê)º¹½Ä ½Ã½ºÅÛ(2´ëÀÇ ÄÄÇ»Å͸¦ ¼³Ä¡Ç쵂 Çϳª´Â ¿¹ºñ¿ë)
  • early-warning system
    (±º)(ÇÙ°ø°Ý¿¡ ´ëÇÑ)Á¶±â °æº¸ Á¶Á÷
  • factory system
    °øÀå Á¦µµ
  • farm system
    Á¦2±º ¸®±× ÇÕµ¿ ¿î¿µÁ¦
  • feudal system
    ºÀ°Ç Á¦µµ
  • fixed exchange rate(system)
    °íÁ¤È¯½Ã¼¼(Á¦)
  • floating exchange rate system
    º¯µ¿ ȯÀ²Á¦
  • fractional orbital bombardment system
    ºÎºÐ ±Ëµµ Æø°Ý üÁ¦
  • freeflying system
    ÀÚÀ¯ ºñÇà ½Ã½ºÅÛ
  • haversian system
    ÇϹö½º°è(ÇϹö½º°ü°ú À̸¦ µÑ·¯ ½Ñ °ñÁ¶Á÷ ³»ÀÇ ±¸¼º ´ÜÀ§)
  • honor system
    ¹«°¨µ¶ ½ÃÇèÁ¦µµ;(Çü¹«¼ÒÀÇ)¹«°¨½Ã Á¦µµ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á